We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+16.8%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$2.63B
AUM Growth
+$690M
Cap. Flow
+$451M
Cap. Flow %
17.16%
Top 10 Hldgs %
21.75%
Holding
1,066
New
264
Increased
497
Reduced
181
Closed
122

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$21.1M
2
MTCH icon
Match Group
MTCH
+$16.7M
3
AMZN icon
Amazon
AMZN
+$15.3M
4
MELI icon
Mercado Libre
MELI
+$13.9M
5
PDD icon
Pinduoduo
PDD
+$13.6M

Top Sells

Rank Stock Value
1
BBBY
Bed Bath & Beyond
BBBY
+$16M
2
PPLI
People Inc
PPLI
+$7.82M
3
ZM icon
Zoom
ZM
+$7.6M
4
KLAC icon
KLA
KLAC
+$7.1M
5
WUBA
58.com Inc
WUBA
+$6.96M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 35.11%
2 Technology 20.8%
3 Communication Services 14.79%
4 Industrials 4.05%
5 Financials 3.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFMD
901
DELISTED
Affimed
AFMD
$2K ﹤0.01%
+72
New +$2.73K
ANIP icon
902
ANI Pharmaceuticals
ANIP
$1.78B
$2K ﹤0.01%
+104
New +$3.1K
AWR icon
903
American States Water
AWR
$3.46B
$2K ﹤0.01%
34
+4
+13% +$307
CLLS
904
Cellectis
CLLS
$285M
$2K ﹤0.01%
+154
New +$2.73K
CTMX icon
905
CytomX Therapeutics
CTMX
$754M
$2K ﹤0.01%
+394
New +$2.92K
DNTH icon
906
Dianthus Therapeutics
DNTH
$6.09B
$2K ﹤0.01%
+26
New +$3.08K
DTIL icon
907
Precision BioSciences
DTIL
$207M
$2K ﹤0.01%
+15
New +$2.98K
PRQR icon
908
ProQR Therapeutics
PRQR
$265M
$2K ﹤0.01%
+426
New +$2.23K
SYRE icon
909
Spyre Therapeutics
SYRE
$9.25B
$2K ﹤0.01%
+15
New +$2.77K
WVE icon
910
Wave Life Sciences
WVE
$1.2B
$2K ﹤0.01%
+310
New +$3.4K
XERS icon
911
Xeris Biopharma Holdings
XERS
$1.45B
$2K ﹤0.01%
+394
New +$1.57K
EIGR
912
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2K ﹤0.01%
+8
New +$2.49K
ORTX
913
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2K ﹤0.01%
+51
New +$2.64K
RVLP
914
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$2K ﹤0.01%
+544
New +$3.13K
CHMA
915
DELISTED
Chiasma, Inc. Common Stock
CHMA
$2K ﹤0.01%
+492
New +$2.36K
PRVL
916
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$2K ﹤0.01%
+292
New +$3.92K
AMAG
917
DELISTED
AMAG Pharmaceuticals
AMAG
$2K ﹤0.01%
+294
New +$2.79K
ADMA icon
918
ADMA Biologics
ADMA
$2.22B
$1K ﹤0.01%
+736
New +$2.02K
AHG
919
Akso Health Group
AHG
$1.16B
$1K ﹤0.01%
916
-1,439
-61% -$3.2K
CNF
920
CNFinance Holdings
CNF
$37.3M
$1K ﹤0.01%
48
-24
-33% -$837
EOLS icon
921
Evolus
EOLS
$501M
$1K ﹤0.01%
+288
New +$1.05K
CBIO
922
Crescent Biopharma
CBIO
$626M
$1K ﹤0.01%
+4
New +$1.53K
LXRX icon
923
Lexicon Pharmaceuticals
LXRX
$1.1B
$1K ﹤0.01%
+910
New +$1.62K
OPTN
924
DELISTED
OptiNose
OPTN
$1K ﹤0.01%
+29
New +$2.15K
UBX
925
DELISTED
Unity Biotechnology
UBX
$1K ﹤0.01%
+44
New +$2.79K
35 36
37
38 39

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Penserra Capital Management held 1,066 positions worth $2.63B, up 36% from $1.94B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Penserra Capital Management deployed $451M of net new capital in Q3 2020, opening 264 new positions and adding to 497 existing holdings. Its largest new stake was Match Group: 157,606 shares worth $17.4M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Bed Bath & Beyond, an estimated $16M trimmed.

  • Penserra Capital Management's largest Q3 2020 buy was Match Group: 157,606 shares worth $17.4M.
  • Penserra Capital Management added most to Alibaba in Q3 2020, an estimated $21.1M increase.
  • Penserra Capital Management's biggest Q3 2020 reduction was Bed Bath & Beyond, cutting an estimated $16M.
  • Penserra Capital Management fully exited 58.com Inc in Q3 2020, selling an estimated $6.96M.
  • Penserra Capital Management's ten largest holdings make up 22% of its $2.63B portfolio in Q3 2020.
  • Penserra Capital Management opened 264 new positions and closed 122 in Q3 2020.
  • Penserra Capital Management's portfolio value rose 36% quarter-over-quarter to $2.63B.

Based on Penserra Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.